Pharmacokinetics and concentration‐effect relationships of intravenous and oral clonidine

The kinetics of the disposition of intravenous and oral clonidine in five normotensive subjects have been determined. It is proposed that a two‐compartment model adequately describes the disposition of the drug. The drug is rapidly distributed (tllza = 10.8 ± 4.7 min) but slowly eliminated (t½β = 8.5 ± 0.9 hr). The bioavailability of oral clonidine in the tablets tested averaged 75.2% and 40 to 50% of the bioavailable dose is excreted unchanged in urine. Renal clearance of the drug showed considerable intersubject variation (1.82 ± 0.34 ml/min/kg) and exceed the calculated glomerular filtration rate in some subjects. Oral and intravenous clonidine induced significant falls in blood pressure (>20/15 mm Hg) in our normotensive subjects and consistently caused marked sedation and dryness of the mouth. Sedation and salivary flow correlated with plasma clonidine concentration over the range 0 to 4 ng/ml. Falls in blood pressure were related to plasma concentration to 1.5 to 2 nglml but at higher concentrations the hypotensive effect was attenuated.

[1]  R. L. Wolf,et al.  PLASMA CLEARANCE OF DL-BETA-H3-NOREPINEPHRINE IN NORMAL HUMAN SUBJECTS AND PATIENTS WITH ESSENTIAL HYPERTENSION. , 1964, The Journal of clinical investigation.

[2]  A. Walland,et al.  Investigations into the mechanism of the hypotensive effect of 2-(2,6-dichlorphenylamino)-2-imidazoline-HCl. , 1967, European journal of pharmacology.

[3]  M. Rowland,et al.  Concept of a volume of distribution and possible errors in evaluation of this parameter. , 1968, Journal of pharmaceutical sciences.

[4]  M. Rowland,et al.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. , 1968, Journal of pharmaceutical sciences.

[5]  S. Riegelman,et al.  New method for calculating the intrinsic absorption rate of drugs. , 1968, Journal of pharmaceutical sciences.

[6]  H. Schmitt Localization of the hypotenisve effect of 2-(2-6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155, Catapresan). , 1969, European journal of pharmacology.

[7]  M. Rand,et al.  Some observations on the inhibition of salivation by St 155 [2-(2,6-dichlorophenylamine)-2-imidazoline hydrochloride, Catapres, Catapresan]. , 1969, European journal of pharmacology.

[8]  V. Dequattro Evaluation of Increased Norepinephrine Excretion in Hypertension Using L‐Dopa‐3H , 1971, Circulation research.

[9]  A. Walland,et al.  Involvement of adrenergic receptors in central vagus activity. , 1971, European journal of pharmacology.

[10]  The effect of clonidine and penbutolol, respectively on catecholamines in blood and urine, plasma renin activity and urinary aldosterone in hypertensive patients. , 1975, Archives internationales de pharmacodynamie et de therapie.

[11]  The Effect of Clonidine on Biochemical Indices of Sympathetic Function in Normotensive Subjects , 1976 .

[12]  J. Reid,et al.  Clinical pharmacology and pharmacokinetics of clonidine , 1976, Clinical pharmacology and therapeutics.

[13]  L. Benet,et al.  The renal elimination of procainamide , 1976, Clinical pharmacology and therapeutics.